VASH1 and ovarian cancer: By WST‐1 assay, paclitaxel chemosensitivity of VASH1‐overexpressing ovarian cancer cells was markedly enhanced compared with that of control cells, whereas there was no significant difference in chemosensitivity to cisplatin.